Loading…
Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression
The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually coll...
Saved in:
| Published in: | Journal of clinical immunology 1989-11, Vol.9 (6), p.454-461 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3 |
| container_end_page | 461 |
| container_issue | 6 |
| container_start_page | 454 |
| container_title | Journal of clinical immunology |
| container_volume | 9 |
| creator | OJO-AMAIZE, E NISHANIAN, P. G HEITJAN, D. F REZAI, A ESMAIL, I KORNS, E DETELS, R FAHEY, J GIORGI, J. V |
| description | The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually collected at 6-month intervals, from individuals at defined stages of HIV disease (seroconversion, the HIV-seropositive period before AIDS, and around the time of clinical AIDS diagnosis) were tested. HIV-coated CEM tumor cells were used as targets. Effector-cell ADCC activity was evaluated using fresh peripheral blood mononuclear cells (PBMC) from HIV-infected individuals at different stages of HIV disease. Samples were obtained from male homosexual participants in the Multicenter AIDS Cohort Study (MACS). In seroconverters, ADCC-inducing HIV-specific antibodies were detected at the time that the ELISA antibody test was first positive. Within several months, serum ADCC activity stabilized in each individual. In 29 HIV-seroprevalent individuals (HIV seropositive on their first visit), serum ADCC activity remained constant regardless of whether the individual's HIV disease was stable (high stable CD4; n = 9) or rapidly deteriorating (sharply declining CD4, n = 10; AIDS progressors, n = 10). With respect to effector-cell activity, PBMC from HIV-infected individuals with or without AIDS were capable of mediating ADCC with heterologous and usually with autologous sera. Although the level of NK cytotoxic activity and the level of antibody-armed effector cell activity have been reported to decline as disease progresses, our results support previous observations that ADCC effector-cell activity against antibody-coated targets does not decline in HIV infection. |
| doi_str_mv | 10.1007/BF00918014 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00918014</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2576558</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EgvLYsEfyggUgBew4jptlKY9WQmLBY1tN7HFrlDiVnSDyLfwsqahgNZpzz8ziEnLK2TVnTN3cPjBW8DHj2Q4ZcalEksoi3SUjliqeFDxLD8hhjB-MMZGncp_sp1LlUo5H5PsFQ1dT8IaitajbJiQaq2ogrSsb0ycG1-gN-pZueFdBoLpvm7b5ctq1Pb2Y3E2nlxR06z43e8AanI905ZYrarrg_JKuuho8dXXd-cagHQ7R655-utBFejGbv19S4yJCRLoOzTJgjK7xx2TPQhXxZDuPyNvD_et0ljw9P86nk6dEC87bRIGweixRlCUzMhM6g1ykPNeSZRKYKgG00qW0A5SyzEwGiGPMQGpR2MKKI3L1-1eHJsaAdrEOrobQLzhbbApe_Bc8yGe_8rorazR_6rbRIT_f5hA1VDaA1y7-abliSqVC_ABn4YXU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression</title><source>SpringerLink Online Journals Archive Complete</source><creator>OJO-AMAIZE, E ; NISHANIAN, P. G ; HEITJAN, D. F ; REZAI, A ; ESMAIL, I ; KORNS, E ; DETELS, R ; FAHEY, J ; GIORGI, J. V</creator><creatorcontrib>OJO-AMAIZE, E ; NISHANIAN, P. G ; HEITJAN, D. F ; REZAI, A ; ESMAIL, I ; KORNS, E ; DETELS, R ; FAHEY, J ; GIORGI, J. V</creatorcontrib><description>The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually collected at 6-month intervals, from individuals at defined stages of HIV disease (seroconversion, the HIV-seropositive period before AIDS, and around the time of clinical AIDS diagnosis) were tested. HIV-coated CEM tumor cells were used as targets. Effector-cell ADCC activity was evaluated using fresh peripheral blood mononuclear cells (PBMC) from HIV-infected individuals at different stages of HIV disease. Samples were obtained from male homosexual participants in the Multicenter AIDS Cohort Study (MACS). In seroconverters, ADCC-inducing HIV-specific antibodies were detected at the time that the ELISA antibody test was first positive. Within several months, serum ADCC activity stabilized in each individual. In 29 HIV-seroprevalent individuals (HIV seropositive on their first visit), serum ADCC activity remained constant regardless of whether the individual's HIV disease was stable (high stable CD4; n = 9) or rapidly deteriorating (sharply declining CD4, n = 10; AIDS progressors, n = 10). With respect to effector-cell activity, PBMC from HIV-infected individuals with or without AIDS were capable of mediating ADCC with heterologous and usually with autologous sera. Although the level of NK cytotoxic activity and the level of antibody-armed effector cell activity have been reported to decline as disease progresses, our results support previous observations that ADCC effector-cell activity against antibody-coated targets does not decline in HIV infection.</description><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/BF00918014</identifier><identifier>PMID: 2576558</identifier><identifier>CODEN: JCIMDO</identifier><language>eng</language><publisher>New York, NY: Kluwer/Plenum</publisher><subject>Analysis of Variance ; Antibody-Dependent Cell Cytotoxicity - immunology ; Biological and medical sciences ; CD4-Positive T-Lymphocytes - immunology ; Cohort Studies ; Cytotoxicity Tests, Immunologic ; HIV - immunology ; HIV Antibodies - biosynthesis ; HIV Antibodies - immunology ; HIV Infections - epidemiology ; HIV Infections - immunology ; HIV Seropositivity - immunology ; HIV-1 - immunology ; Humans ; Immunodeficiencies ; Immunodeficiencies. Immunoglobulinopathies ; Immunopathology ; Leukocyte Count ; Leukocytes, Mononuclear - immunology ; Los Angeles - epidemiology ; Male ; Medical sciences ; Multicenter Studies as Topic</subject><ispartof>Journal of clinical immunology, 1989-11, Vol.9 (6), p.454-461</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3</citedby><cites>FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6707723$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2576558$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>OJO-AMAIZE, E</creatorcontrib><creatorcontrib>NISHANIAN, P. G</creatorcontrib><creatorcontrib>HEITJAN, D. F</creatorcontrib><creatorcontrib>REZAI, A</creatorcontrib><creatorcontrib>ESMAIL, I</creatorcontrib><creatorcontrib>KORNS, E</creatorcontrib><creatorcontrib>DETELS, R</creatorcontrib><creatorcontrib>FAHEY, J</creatorcontrib><creatorcontrib>GIORGI, J. V</creatorcontrib><title>Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><description>The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually collected at 6-month intervals, from individuals at defined stages of HIV disease (seroconversion, the HIV-seropositive period before AIDS, and around the time of clinical AIDS diagnosis) were tested. HIV-coated CEM tumor cells were used as targets. Effector-cell ADCC activity was evaluated using fresh peripheral blood mononuclear cells (PBMC) from HIV-infected individuals at different stages of HIV disease. Samples were obtained from male homosexual participants in the Multicenter AIDS Cohort Study (MACS). In seroconverters, ADCC-inducing HIV-specific antibodies were detected at the time that the ELISA antibody test was first positive. Within several months, serum ADCC activity stabilized in each individual. In 29 HIV-seroprevalent individuals (HIV seropositive on their first visit), serum ADCC activity remained constant regardless of whether the individual's HIV disease was stable (high stable CD4; n = 9) or rapidly deteriorating (sharply declining CD4, n = 10; AIDS progressors, n = 10). With respect to effector-cell activity, PBMC from HIV-infected individuals with or without AIDS were capable of mediating ADCC with heterologous and usually with autologous sera. Although the level of NK cytotoxic activity and the level of antibody-armed effector cell activity have been reported to decline as disease progresses, our results support previous observations that ADCC effector-cell activity against antibody-coated targets does not decline in HIV infection.</description><subject>Analysis of Variance</subject><subject>Antibody-Dependent Cell Cytotoxicity - immunology</subject><subject>Biological and medical sciences</subject><subject>CD4-Positive T-Lymphocytes - immunology</subject><subject>Cohort Studies</subject><subject>Cytotoxicity Tests, Immunologic</subject><subject>HIV - immunology</subject><subject>HIV Antibodies - biosynthesis</subject><subject>HIV Antibodies - immunology</subject><subject>HIV Infections - epidemiology</subject><subject>HIV Infections - immunology</subject><subject>HIV Seropositivity - immunology</subject><subject>HIV-1 - immunology</subject><subject>Humans</subject><subject>Immunodeficiencies</subject><subject>Immunodeficiencies. Immunoglobulinopathies</subject><subject>Immunopathology</subject><subject>Leukocyte Count</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Los Angeles - epidemiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multicenter Studies as Topic</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><recordid>eNpFkMtOwzAQRS0EgvLYsEfyggUgBew4jptlKY9WQmLBY1tN7HFrlDiVnSDyLfwsqahgNZpzz8ziEnLK2TVnTN3cPjBW8DHj2Q4ZcalEksoi3SUjliqeFDxLD8hhjB-MMZGncp_sp1LlUo5H5PsFQ1dT8IaitajbJiQaq2ogrSsb0ycG1-gN-pZueFdBoLpvm7b5ctq1Pb2Y3E2nlxR06z43e8AanI905ZYrarrg_JKuuho8dXXd-cagHQ7R655-utBFejGbv19S4yJCRLoOzTJgjK7xx2TPQhXxZDuPyNvD_et0ljw9P86nk6dEC87bRIGweixRlCUzMhM6g1ykPNeSZRKYKgG00qW0A5SyzEwGiGPMQGpR2MKKI3L1-1eHJsaAdrEOrobQLzhbbApe_Bc8yGe_8rorazR_6rbRIT_f5hA1VDaA1y7-abliSqVC_ABn4YXU</recordid><startdate>19891101</startdate><enddate>19891101</enddate><creator>OJO-AMAIZE, E</creator><creator>NISHANIAN, P. G</creator><creator>HEITJAN, D. F</creator><creator>REZAI, A</creator><creator>ESMAIL, I</creator><creator>KORNS, E</creator><creator>DETELS, R</creator><creator>FAHEY, J</creator><creator>GIORGI, J. V</creator><general>Kluwer/Plenum</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19891101</creationdate><title>Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression</title><author>OJO-AMAIZE, E ; NISHANIAN, P. G ; HEITJAN, D. F ; REZAI, A ; ESMAIL, I ; KORNS, E ; DETELS, R ; FAHEY, J ; GIORGI, J. V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Analysis of Variance</topic><topic>Antibody-Dependent Cell Cytotoxicity - immunology</topic><topic>Biological and medical sciences</topic><topic>CD4-Positive T-Lymphocytes - immunology</topic><topic>Cohort Studies</topic><topic>Cytotoxicity Tests, Immunologic</topic><topic>HIV - immunology</topic><topic>HIV Antibodies - biosynthesis</topic><topic>HIV Antibodies - immunology</topic><topic>HIV Infections - epidemiology</topic><topic>HIV Infections - immunology</topic><topic>HIV Seropositivity - immunology</topic><topic>HIV-1 - immunology</topic><topic>Humans</topic><topic>Immunodeficiencies</topic><topic>Immunodeficiencies. Immunoglobulinopathies</topic><topic>Immunopathology</topic><topic>Leukocyte Count</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Los Angeles - epidemiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multicenter Studies as Topic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>OJO-AMAIZE, E</creatorcontrib><creatorcontrib>NISHANIAN, P. G</creatorcontrib><creatorcontrib>HEITJAN, D. F</creatorcontrib><creatorcontrib>REZAI, A</creatorcontrib><creatorcontrib>ESMAIL, I</creatorcontrib><creatorcontrib>KORNS, E</creatorcontrib><creatorcontrib>DETELS, R</creatorcontrib><creatorcontrib>FAHEY, J</creatorcontrib><creatorcontrib>GIORGI, J. V</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>OJO-AMAIZE, E</au><au>NISHANIAN, P. G</au><au>HEITJAN, D. F</au><au>REZAI, A</au><au>ESMAIL, I</au><au>KORNS, E</au><au>DETELS, R</au><au>FAHEY, J</au><au>GIORGI, J. V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression</atitle><jtitle>Journal of clinical immunology</jtitle><addtitle>J Clin Immunol</addtitle><date>1989-11-01</date><risdate>1989</risdate><volume>9</volume><issue>6</issue><spage>454</spage><epage>461</epage><pages>454-461</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><coden>JCIMDO</coden><abstract>The activity of both serum and effector cell antibody-dependent cellular cytotoxicity (ADCC) against human immunodeficiency virus (HIV-1, HIV) was assessed in HIV-infected individuals. The goal was to relate ADCC levels with the stage or progression of HIV disease. Serial serum samples, usually collected at 6-month intervals, from individuals at defined stages of HIV disease (seroconversion, the HIV-seropositive period before AIDS, and around the time of clinical AIDS diagnosis) were tested. HIV-coated CEM tumor cells were used as targets. Effector-cell ADCC activity was evaluated using fresh peripheral blood mononuclear cells (PBMC) from HIV-infected individuals at different stages of HIV disease. Samples were obtained from male homosexual participants in the Multicenter AIDS Cohort Study (MACS). In seroconverters, ADCC-inducing HIV-specific antibodies were detected at the time that the ELISA antibody test was first positive. Within several months, serum ADCC activity stabilized in each individual. In 29 HIV-seroprevalent individuals (HIV seropositive on their first visit), serum ADCC activity remained constant regardless of whether the individual's HIV disease was stable (high stable CD4; n = 9) or rapidly deteriorating (sharply declining CD4, n = 10; AIDS progressors, n = 10). With respect to effector-cell activity, PBMC from HIV-infected individuals with or without AIDS were capable of mediating ADCC with heterologous and usually with autologous sera. Although the level of NK cytotoxic activity and the level of antibody-armed effector cell activity have been reported to decline as disease progresses, our results support previous observations that ADCC effector-cell activity against antibody-coated targets does not decline in HIV infection.</abstract><cop>New York, NY</cop><pub>Kluwer/Plenum</pub><pmid>2576558</pmid><doi>10.1007/BF00918014</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0271-9142 |
| ispartof | Journal of clinical immunology, 1989-11, Vol.9 (6), p.454-461 |
| issn | 0271-9142 1573-2592 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00918014 |
| source | SpringerLink Online Journals Archive Complete |
| subjects | Analysis of Variance Antibody-Dependent Cell Cytotoxicity - immunology Biological and medical sciences CD4-Positive T-Lymphocytes - immunology Cohort Studies Cytotoxicity Tests, Immunologic HIV - immunology HIV Antibodies - biosynthesis HIV Antibodies - immunology HIV Infections - epidemiology HIV Infections - immunology HIV Seropositivity - immunology HIV-1 - immunology Humans Immunodeficiencies Immunodeficiencies. Immunoglobulinopathies Immunopathology Leukocyte Count Leukocytes, Mononuclear - immunology Los Angeles - epidemiology Male Medical sciences Multicenter Studies as Topic |
| title | Serum and effector-cell antibody-dependent cellular cytotoxicity (ADCC) activity remains high during human immunodeficiency virus (HIV) disease progression |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T21%3A23%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20and%20effector-cell%20antibody-dependent%20cellular%20cytotoxicity%20(ADCC)%20activity%20remains%20high%20during%20human%20immunodeficiency%20virus%20(HIV)%20disease%20progression&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=OJO-AMAIZE,%20E&rft.date=1989-11-01&rft.volume=9&rft.issue=6&rft.spage=454&rft.epage=461&rft.pages=454-461&rft.issn=0271-9142&rft.eissn=1573-2592&rft.coden=JCIMDO&rft_id=info:doi/10.1007/BF00918014&rft_dat=%3Cpubmed_cross%3E2576558%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-7a3fc85e3bb0d543c4a63216c5045a07baac7cb5f32155b4d4aee8e4a5c39f9f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/2576558&rfr_iscdi=true |